Competitive Outlook on Non-Antibody Based Cancer Vaccines

New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.

Scope of this report

In-depth competitive landscape assessment of the cancer vaccine market

Tumor antigen discovery and technologies surrounding it

Thorough review of immunomodulating strategies and adjuvants

Thorough review of cancer vaccine delivery and technologies surrounding it

Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.

Key reasons to read this report

Understand the clinical and strategic challenges to the commercialization of cancer vaccines

Assess opportunities and risks for the continued development of cancer vaccines in six major cancer indications.

Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

August 2006 Pages 138
Table of Contents
Price: $2,999.00 / GBP1,499.50